Atossa Therapeutics Posts Q3 2026 Financial Results, Updates Pipeline

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a Seattle-based clinical-stage biopharmaceutical company, disclosed its financial results for the third quarter of 2026 on Monday, alongside a corporate update covering its drug development programs in oncology and other therapeutic areas with significant unmet medical need.

The company, which focuses on developing novel treatment approaches for cancer patients, provided investors with a snapshot of its operational and financial standing through the quarter. Atossa has positioned itself within a competitive oncology development landscape where clinical-stage firms face ongoing pressure to advance pipeline assets while managing cash resources carefully.

Read more Cisco Posts Record $18.5B Revenue, EPS Surges in Q1 2027 →

As a clinical-stage enterprise, Atossa does not yet generate product revenue, making its quarterly disclosures particularly important for investors tracking spending rates, cash runway, and trial milestones. The corporate update portion of Monday's announcement was expected to address the status of key clinical programs that underpin the company's long-term valuation thesis.

Atossa's listing on the Nasdaq exchange under the ticker ATOS gives retail and institutional investors direct exposure to its pipeline risk and reward profile. Quarterly earnings releases serve as a primary mechanism through which the company communicates both financial discipline and scientific progress to the market.

Continue reading at Earnings for the full financial tables and complete corporate update details.